An Abrysvo-Shaped Hole: CDC Panel’s Beyfortus Vote Couldn’t Consider Pfizer’s Pending Vaccine
The prospect of a game-changing approval of Pfizer’s maternal RSV vaccine hung over CDC committee’s vote on AstraZeneca/Sanofi’s Beyfortus, even though the pending product could not be addressed.
You may also be interested in...
Abrysvo is recommended for use in pregnant people 32-36 weeks gestation if administered from September to January. For infants whose mothers were not vaccinated in this window, nirsevimab is recommended for prevention of respiratory syncytial virus infection.
GLP-1 agonists are creating a stir in obesity management and could possibly prevent non-alcoholic fatty liver disease, with implications for developers of NAFLD treatments. Similarly, another preventative intervention might succeed the treatments for Alzheimer’s disease.
CDC advisory committee unanimously recommends Sanofi/AstraZeneca’s monoclonal antibody for infants in their first respiratory syncytial virus season and high-risk babies and American Indian children in their second RSV season.